Please wait while we load the requested 10-Q report or click the link below:
AEGERION PHARMACEUTICALS ANNOUNCES
THIRD QUARTER 2015 FINANCIAL RESULTS
Company records $67.3 million in total net product sales -
Cambridge, MA, November 9, 2015 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business highlights for the third quarter of 2015.
Chief Executive Officer Sandford D. Smith commented, “In the third quarter, we executed well on a number of Aegerion’s key strategic objectives by maintaining a strong focus on our current commercial products and progressing towards broader market access for LOJUXTA in Europe. We are managing JUXTAPID through volatile market dynamics associated with the introduction of PCSK9 inhibitors. In addition, we continue to identify generalized lipodystrophy patients and bring them on to MYALEPT. We view MYALEPT as an important and steady growth driver.
“We made progress towards supporting the long-term growth of Aegerion through a strategic plan that prioritizes Aegerion’s life cycle management and business development initiatives. Deepening Aegerion’s pipeline with opportunities for both MYALEPT and JUXTAPID, as well as potential new assets, remains an important objective. We expect that these efforts, combined with our ongoing expansion into both European and other international markets, will support meaningful future growth.”
The following information was filed by Aegerion Pharmaceuticals, Inc. (AEGR) on Monday, November 9, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Aegerion Pharmaceuticals, Inc..